EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination Codons

Nesrine Benslimane iD, Camille Loret iD, Pauline Chazelas, Frédéric Favreau iD, Pierre-Antoine Faye iD, Fabrice Lejeune iD, Anne-Sophie Lia iD

Pharmaceuticals · 28.02.2024 · 17 (3) · 314

DOI: 10.3390/ph17030314 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 28.02.2024. Verfasst von Nesrine Benslimane und 6 weiteren Autor:innen. Beteiligte Einrichtung: GEIST Institute, University of Limoges, NeurIT UR 20218, F-87000 Limoges, France. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Région Nouvelle Aquitaine, Association pour l’encouragement à la recherche en neurologie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonsense mutations that generate a premature termination codon (PTC) can induce both the accelerated degradation of mutated mRNA compared with the wild type version of the mRNA or the production of a truncated protein. One of the considered therapeutic strategies to bypass PTCs is their “readthrough” based on small-molecule drugs. These molecules promote the incorporation of a near-cognate tRNA at the PTC position through the native polypeptide chain. In this review, we detailed the various existing strategies organized according to pharmacological molecule types through their different mechanisms. The positive results that followed readthrough molecule testing in multiple neuromuscular disorder models indicate the potential of this approach in peripheral neuropathies.

Schlagwörter

Stichwörter der Autor:innen

genetic diseasenonsense mutationnonsense-mediated mRNA decay (NMD)premature termination codon (PTC)readthroughtranslation

Autor:innen und Institutionen

  • GEIST Institute, University of Limoges, NeurIT UR 20218, F-87000 Limoges, France.
  • Centre Hospitalo-Universitaire (CHU) Limoges, Department of Biochemistry and Molecular Genetics, F-87000 Limoges, France.
  • University of Lille, Centre National de la Recherche Scientifique, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Centre Hospitalo-Universitaire (CHU) Limoges, Department of Bioinformatics, F-87000 Limoges, France.

ORCID-Profile: Nesrine Benslimane, Camille Loret, Frédéric Favreau, Pierre-Antoine Faye, Fabrice Lejeune, Anne-Sophie Lia

Förderung

  • Agence Nationale de la Recherche
  • Région Nouvelle Aquitaine
  • Association pour l’encouragement à la recherche en neurologie

Zitieren

APA

Benslimane, N., Loret, C., Chazelas, P., Favreau, F., Faye, P. A., Lejeune, F., & Lia, A. S. (2024). Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination Codons. Pharmaceuticals, 17(3), 314. https://doi.org/10.3390/ph17030314

Vancouver

Benslimane N, Loret C, Chazelas P, Favreau F, Faye PA, Lejeune F, et al. Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination Codons. Pharmaceuticals. 2024;17(3):314. doi:10.3390/ph17030314

BibTeX
@article{Benslimane2024,
  author = {Benslimane, Nesrine and Loret, Camille and Chazelas, Pauline and Favreau, Frédéric and Faye, Pierre-Antoine and Lejeune, Fabrice and Lia, Anne-Sophie},
  title = {Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination Codons},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {3},
  pages = {314},
  doi = {10.3390/ph17030314}
}
Kostenlos starten →